Rationally Designing Monovalent Targeted Protein Degrader Therapeutics
Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues. Our small molecule compounds are being developed as potential first-in-class and best-in-class treatments for high unmet medical needs.
Our pipeline is powered by our DELTA Discovery™ platform, including a proprietary ultra-high throughput (uHTS) cell-based screening capability that has supported the advancement of multiple clinical-stage protein degraders. We leverage a suite of enabling technologies that expand the “druggable” target space for TPD and beyond.
Meet Our Team
At Plexium, we are bound by our shared commitment to delivering life-changing medicines to patients. Our highly collaborative team is rooted in an entrepreneurial spirit that fuels our innovation.
Leon Chen, Ph.D.
Partner, The Column Group
Cariad Chester
Partner, TCG X
Mike Grey
Executive Chairman, Plexium
Rob Hopfner, Ph.D.
Managing Partner, Pivotal Bioventure Partners
Gorjan Hrustanovic, Ph.D.
Managing Director, BVF Partners L.P.
Michael Martin, Ph.D.
Chief Executive Officer, President, Plexium
Serge Messerlian
Operating Partner, DCVC Bio
Patrick Rivers
Portfolio Manager, aMoon
